Field-by-field guide to interpreting a research peptide Certificate of Analysis — HPLC purity, MS identity, Karl Fischer, endotoxin, batch traceability, and red flags.
10-point framework for evaluating research peptide suppliers — third-party HPLC, COA standards, regulatory compliance posture, sourcing transparency, and red flags.
Four-peptide multi-system longevity research protocol — mitochondrial biogenesis, mitochondrial optimization, neuroprotection, and tissue remodeling combined.
Pillar guide to recovery research peptides — BPC-157, TB-500, KPV, GHK-Cu — covering the three-phase repair cascade and 2024–2026 stack research.
What published research actually says about BPC-157 and TB-500 — sequences, study models, human-evidence gaps, and why no combination study exists.
Plain-language explanation of FDA regulations for research peptides, ‘for research only’ labeling rules, 2025–2026 enforcement actions, and state-level variation.
SLU-PP-332 ERRα agonist deep dive — mechanism, the 2023 Saint Louis University publication, exercise-mimetic transcriptional signature, and 2024-2026 follow-up research.
Pillar guide to longevity research peptides — MOTS-C, SS-31 (elamipretide), SLU-PP-332, GHK-Cu, 5-Amino-1MQ — mechanisms, 2024–2026 data, and comparative pharmacology.
Pillar guide to cognitive enhancement research peptides — Semax, Selank, DSIP, VIP, Oxytocin — covering BDNF, GABA, and neuroplasticity mechanisms in 2024–2026 literature.
TRIUMPH-4 retatrutide Phase 3 trial design — Phase 3 outcomes pending; Phase 2 data (PMID 37366315) shows up to 24.2% mean weight reduction at 48 weeks (12 mg).